• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    1/9/23 4:31:00 PM ET
    $APGN
    $BLI
    $CLSD
    $CMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $APGN alert in real time by email

    Gainers

    • VYNE Therapeutics (NASDAQ:VYNE) shares rose 87.0% to $0.36 during Monday's after-market session. At the close, VYNE Therapeutics's trading volume reached 2.9 million shares. This is 590.3% of its average volume over the last 100 days. The company's market cap stands at $20.8 million.
    • Clearside Biomedical (NASDAQ:CLSD) stock increased by 12.41% to $1.81. The market value of their outstanding shares is at $108.9 million.
    • Nuwellis (NASDAQ:NUWE) shares increased by 12.01% to $10.44. Nuwellis's trading volume hit 230.9K shares by close, accounting for 92.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $5.5 million.
    • First Wave BioPharma (NASDAQ:FWBI) shares increased by 7.69% to $0.98. First Wave BioPharma's trading volume hit 119.0K shares by close, accounting for 12.2% of its average volume over the last 100 days. The company's market cap stands at $5.6 million.
    • Idera Pharmaceuticals (NASDAQ:IDRA) shares increased by 6.14% to $0.71. The market value of their outstanding shares is at $44.2 million.
    • Sutro Biopharma (NASDAQ:STRO) shares moved upwards by 6.03% to $8.79. The market value of their outstanding shares is at $505.2 million.

    Losers

    • G Medical Innovations (NASDAQ:GMVD) shares fell 12.3% to $3.86 during Monday's after-market session. At the close, G Medical Innovations's trading volume reached 113.4K shares. This is 266.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.8 million.
    • Apexigen (NASDAQ:APGN) shares decreased by 8.34% to $1.65. Today's trading volume for this security ended up closing at 8.3 million shares, which is 22539.5 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $37.2 million.
    • Berkeley Lights (NASDAQ:BLI) shares decreased by 7.93% to $2.44. The market value of their outstanding shares is at $168.0 million.
    • Iterum Therapeutics (NASDAQ:ITRM) shares fell 7.7% to $0.9. The company's market cap stands at $11.0 million.
    • IsoPlexis (NASDAQ:ISO) stock decreased by 7.65% to $1.45. The market value of their outstanding shares is at $58.4 million.
    • Comera Life Sciences (NASDAQ:CMRA) stock declined by 7.37% to $1.76. The company's market cap stands at $34.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APGN
    $BLI
    $CLSD
    $CMRA

    CompanyDatePrice TargetRatingAnalyst
    Sutro Biopharma Inc.
    $STRO
    3/24/2026$27.00Equal Weight → Overweight
    Wells Fargo
    Sutro Biopharma Inc.
    $STRO
    3/24/2026$28.00Neutral → Buy
    H.C. Wainwright
    Sutro Biopharma Inc.
    $STRO
    1/20/2026$23.00Mkt Perform → Mkt Outperform
    Citizens JMP
    VYNE Therapeutics Inc.
    $VYNE
    7/31/2025Buy → Neutral
    BTIG Research
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025$2.00Buy → Hold
    Stifel
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025Buy → Neutral
    Chardan Capital Markets
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025Buy → Neutral
    H.C. Wainwright
    Sutro Biopharma Inc.
    $STRO
    6/16/2025$2.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $APGN
    $BLI
    $CLSD
    $CMRA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug XIPERE (ORIG-1) with active ingredient TRIAMCINOLONE ACETONIDE has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:22:37 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SUSVIMO issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug SUSVIMO (ORIG-1) with active ingredient RANIBIZUMAB has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:07:19 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $BLI
    $CLSD
    $CMRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dunne Michael W. bought $2,191 worth of Ordinary Shares (6,000 units at $0.37), increasing direct ownership by 3% to 241,001 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    11/20/25 7:00:04 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Gerber Hans-Peter bought $13,607 worth of shares (17,000 units at $0.80), increasing direct ownership by 31% to 71,832 units (SEC Form 4)

    4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

    10/16/25 8:19:45 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CFO Chow Gregory K. bought $15,998 worth of shares (19,750 units at $0.81) (SEC Form 4)

    4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

    10/16/25 8:18:45 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $BLI
    $CLSD
    $CMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sutro Biopharma upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Sutro Biopharma from Equal Weight to Overweight and set a new price target of $27.00

    3/24/26 8:28:11 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sutro Biopharma upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Sutro Biopharma from Neutral to Buy and set a new price target of $28.00

    3/24/26 8:28:11 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sutro Biopharma upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Sutro Biopharma from Mkt Perform to Mkt Outperform and set a new price target of $23.00

    1/20/26 8:48:34 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $BLI
    $CLSD
    $CMRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

    – Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned dual-payload program targeting PTK7, STRO-227, accelerating IND submission to 2026 – – Astellas-partnered iADC dual-payload program enters the clinic; patient dosing underway – – Cash, cash equivalents and marketable securities as of December 31, 2025 of $141.4 million, excluding proceeds from the recent capital raise of approximately $110 million which extended cash runway into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma,

    3/23/26 4:05:00 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nuwellis Completes Acquisition of Rendiatech

    MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the completion of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. Rendiatech has no commercial operations and was formed to acquire certain assets of RenalSense Ltd. following its bankruptcy proceedings; the Company purchased Rendiatech primarily to gain access to such assets. The purchase expands Nuwellis' capabilities across the card

    3/17/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APGN
    $BLI
    $CLSD
    $CMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Emerson Martin J

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    3/18/26 4:26:10 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Admin. Ofcr. & GC Pauling David converted options into 675 shares and covered exercise/tax liability with 277 shares, increasing direct ownership by 4% to 9,748 units (SEC Form 4)

    4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

    3/6/26 4:25:03 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Chung Jane converted options into 788 shares and covered exercise/tax liability with 282 shares, increasing direct ownership by 2% to 21,285 units (SEC Form 4)

    4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

    3/6/26 4:21:10 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $BLI
    $CLSD
    $CMRA
    SEC Filings

    View All

    SEC Form S-3 filed by Sutro Biopharma Inc.

    S-3 - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

    3/23/26 5:23:05 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Sutro Biopharma Inc.

    S-8 - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

    3/23/26 5:10:25 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Sutro Biopharma Inc.

    10-K - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

    3/23/26 4:44:40 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $BLI
    $CLSD
    $CMRA
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints Carisa Schultz as Chief Financial Officer

    MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including A

    1/30/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APGN
    $BLI
    $CLSD
    $CMRA
    Financials

    Live finance-specific insights

    View All

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: N

    2/24/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

    Following closing, combined company plans to progress Yarrow's lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor ("TSHR") antibody for Graves' disease ("GD") and thyroid eye disease ("TED")Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in China by partner Changchun GeneScience Pharmaceutical Co., Ltd ("GenSci")Pre-closing private financings totaling approximately $200 million expected to fund operations into 2028Companies to

    12/17/25 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $BLI
    $CLSD
    $CMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sutro Biopharma Inc.

    SC 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)

    11/14/24 7:54:45 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Iterum Therapeutics plc

    SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)

    11/14/24 7:54:21 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sutro Biopharma Inc.

    SC 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)

    11/14/24 4:30:53 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care